![]() |
|
|
Vol. 284, Issue 3, 1156-1164, March 1998
Department of Medicine (H.S., X.-p.G, I.R.),
University of Illinois at Chicago and West Side Department of Veterans
Affairs Medical Center, Chicago, Illinois, and Cardiovascular Research
Institute and Department of Medicine (G.H.C.),
University of California, San Francisco, California
This study investigated whether short-term exposure to
Escherichia coli lipopolysaccharide (LPS) elicits
vasomotor dysfunction in skeletal muscle in vivo and, if
so, whether perivascular mast cell proteases partly modulate this
response. With intravital microscopy, we found that suffusion of
E. coli LPS on the in situ hamster
spinotrapezius muscle for 60 min elicits immediate vasoconstriction followed by vasodilation. Vasoconstriction is abrogated by SK&F 108566, a selective, nonpeptide angiotensin II (AT II) subtype 1 receptor
antagonist, chymostatin and soybean trypsin inhibitor. These compounds
also attenuate E. coli LPS-induced vasodilation. By
contrast, superoxide dismutase, catalase and indomethacin attenuate only E. coli LPS-induced vasodilation. Endothelin
receptor antagonists, lisinopril, leupeptin, Bestatin and
DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid are
ineffective. Histochemical analysis of the spinotrapezius muscle
reveals abundant perivascular mast cells with chymostatin-inhibitable chymase-like activity. Pretreatment of hamsters with compound 48/80 for
4 days curtails E. coli LPS-induced vasoconstriction and
converts vasodilation to vasoconstriction. On balance, these data
indicate that E. coli LPS stimulates perivascular mast
cells in the in situ hamster spinotrapezius muscle to
release an AT II-producing chymase-like protease(s). AT II thus
produced elicits local vasoconstriction and elaborates reactive oxygen
species which, in turn, generate vasodilator prostaglandins.
This article has been cited by other articles:
![]() |
H. Suzuki, H. Ikezaki, R. Chandiwala, D. Hong, and I. Rubinstein Effects of Pseudomonas aeruginosa endotoxin on vasodilation in the intact spinotrapezius muscle J Appl Physiol, July 1, 2001; 91(1): 351 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Rubinstein, J. Potempa, J. Travis, and X.-P. Gao Mechanisms Mediating Porphyromonas gingivalis Gingipain RgpA-Induced Oral Mucosa Inflammation In Vivo Infect. Immun., February 1, 2001; 69(2): 1199 - 1201. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Arakawa and H. Urata Hypothesis Regarding the Pathophysiological Role of Alternative Pathways of Angiotensin II Formation in Atherosclerosis Hypertension, October 1, 2000; 36(4): 638 - 641. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Rubinstein Subtilisin Increases Macromolecular Efflux from the Oral Mucosa Clin. Vaccine Immunol., September 1, 2000; 7(5): 794 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ikezaki, H. Onyuksel, and I. Rubinstein Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo Am J Physiol Regulatory Integrative Comp Physiol, August 1, 1998; 275(2): R588 - R595. [Abstract] [Full Text] [PDF] |
||||